

James A Fagin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3527975/james-a-fagin-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154
papers

17,089
citations

65
h-index

130
g-index

163
ext. papers

19,538
ext. citations

9.6
avg, IF

6.36
L-index

#	Paper	IF	Citations
154	Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.. <i>Thyroid</i> , 2022 ,	6.2	5
153	Age of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102864	2.2	
152	Prolonged survival of anaplastic thyroid carcinoma is associated with resectability, low tumor-infiltrating neutrophils/myeloid-derived suppressor cells, and low peripheral neutrophil-to-lymphocyte ratio.. <i>Endocrine</i> , 2022 , 1	4	1
151	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.. <i>Head and Neck</i> , 2022 ,	4.2	2
150	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.. <i>Nature Communications</i> , 2022 , 13, 1450	17.4	1
149	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2100714	2.2	4
148	International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101329	2.2	5
147	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. <i>Molecular Cancer Research</i> , 2021 ,	6.6	2
146	Context-dependent modulation of aggressiveness of pediatric tumors by individual oncogenic RAS isoforms. <i>Oncogene</i> , 2021 , 40, 4955-4966	9.2	1
145	Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. <i>Endocrine-Related Cancer</i> , 2021 , 28, 391-402	5.7	6
144	Ultrasound-Guided Percutaneous Laser Ablation of the Thyroid Gland in a Swine Model: Comparison of Ablation Parameters and Ablation Zone Dimensions. <i>CardioVascular and Interventional Radiology</i> , 2021 , 44, 1798-1806	2.7	1
143	SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. <i>Cancer Discovery</i> , 2021 , 11, 1158-1175	24.4	16
142	Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. <i>Cancer</i> , 2021 , 127, 4161-4170	6.4	0
141	Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. <i>Histopathology</i> , 2021 ,	7.3	3
140	Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	1
139	Oncogene-induced DNA damage: cyclic AMP steps into the ring. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5668-5670	15.9	1
138	Dynamic contrast-enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers. <i>NMR in Biomedicine</i> , 2020 , 33, e4166	4.4	9

137	Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake. <i>Cancer Research</i> , 2020 , 80, 102-115	10.1	11
136	Therapeutic breakthroughs for metastatic thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2020 , 16, 77-78	15.2	18
135	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020 , 52, 1219-1226	26.3	103
134	Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. <i>Thyroid</i> , 2020 , 30, 1505-1517	6.2	51
133	Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4889-4899	5.6	15
132	Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features. <i>Endocrine</i> , 2019 , 64, 97-108	4	20
131	Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. <i>Molecular Cancer Research</i> , 2019 , 17, 1036-1048	6.6	5
130	Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. <i>Clinical Cancer Research</i> , 2019 , 25, 3141-3151	12.9	50
129	Genetics of Human Thyroid Cancer Cell Lines-Response. <i>Clinical Cancer Research</i> , 2019 , 25, 6883-6884	12.9	2
128	Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness. <i>Thyroid</i> , 2019 , 29, 79-92	6.2	12
127	Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 1417-1428	5.6	80
126	and Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. <i>Cancer Discovery</i> , 2019 , 9, 264-281	24.4	34
125	Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia. <i>Molecular and Cellular Endocrinology</i> , 2018 , 460, 24-35	4.4	7
124	Integrated Genomic Analysis of Httle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. <i>Cancer Cell</i> , 2018 , 34, 256-270.e5	24.3	103
123	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. <i>Thyroid</i> , 2018 , 28, 1180-1189	6.2	14
122	Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4086-4097	15.9	33
121	Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 4216-4223	5.6	18
120	Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 3169-3182	5.6	6

119	Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. <i>Cancer Research</i> , 2018 , 78, 4642-4657	10.1	36
118	AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. <i>Head and Neck</i> , 2018 , 40, 1881-1888	4.2	29
117	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of and as Novel Thyroid Cancer Genes Associated with Tumor Virulence. <i>Clinical Cancer Research</i> , 2017 , 23, 5970-5980	12.8	64
116	Transposon mutagenesis identifies chromatin modifiers cooperating with in thyroid tumorigenesis and detects as a cancer gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E4951-E4960	11.5	9
115	Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017 , 143, 1015-1020	3.9	219
114	Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. <i>Cancer</i> , 2017 , 123, 4114-4121	6.4	42
113	Comparison of Empiric Versus Whole-Body/Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 717-722	8.9	55
112	NADPH Oxidase NOX4 Is a Critical Mediator of BRAF-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas. <i>Antioxidants and Redox Signaling</i> , 2017 , 26, 864-877	8.4	41
111	Biologic and Clinical Perspectives on Thyroid Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1054-67	59.2	405
110	Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. <i>Modern Pathology</i> , 2016 , 29, 985-95	9.8	62
109	Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1052-66	15.9	576
108	Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. <i>Journal of Clinical Investigation</i> , 2016 , 126, 4119-4124	15.9	71
107	Biologic and Clinical Perspectives on Thyroid Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 2307	59.2	66
106	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. <i>Cancer Cell</i> , 2016 , 30, 485-498	24.3	80
105	Therapy: Lenvatinib and radioiodine-refractory thyroid cancers. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 325-7	15.2	8
104	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. <i>Nature</i> , 2015 , 526, 453-7	50.4	144
103	Response to: Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma". <i>Thyroid</i> , 2015 , 25, 1269-70	6.2	
102	NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. <i>Cancer Discovery</i> , 2015 , 5, 1178-93	24.4	78

101	Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. <i>Thyroid</i> , 2015 , 25, 300-7	6.2	94
100	Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation. <i>Human Molecular Genetics</i> , 2014 , 23, 682-92	5.6	31
99	Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. <i>Endocrine-Related Cancer</i> , 2014 , 21, 371-81	5.7	302
98	Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E1976-87	5.6	21
97	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1493-501	27.4	605
96	Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 623-32	59.2	524
95	Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E364-9	5.6	157
94	Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E962-72	5.6	139
93	Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1414-21	5.6	66
92	Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1562-6	5.6	299
91	Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. <i>Endocrine-Related Cancer</i> , 2013 , 20, 659-67	5.7	43
90	Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. <i>Cancer Discovery</i> , 2013 , 3, 520-33	24.4	266
89	Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. <i>PLoS ONE</i> , 2013 , 8, e54302	3.7	99
88	Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4935-44	15.9	155
87	Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. <i>International Journal of Cancer</i> , 2012 , 130, 2215-7; author reply 2217-8	7.5	4
86	Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. <i>Cancer Cell</i> , 2012 , 22, 668-82	24.3	377
85	Reply to J.-F. Chatal et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2166-2167	2.2	
84	Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. <i>Thyroid</i> , 2012 , 22, 575-84	6.2	95

83	STAT3 negatively regulates thyroid tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E2361-70	11.5	99
82	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. <i>Journal of Clinical Investigation</i> , 2011 , 121, 4700-11	15.9	232
81	The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. <i>Endocrine-Related Cancer</i> , 2011 , 18, 1-11	5.7	52
80	Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. <i>Thyroid</i> , 2011 , 21, 845-53	6.2	94
79	Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 1615-20	11.5	149
78	Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. <i>Thyroid</i> , 2010 , 20, 1341-9	6.2	606
77	Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. <i>Modern Pathology</i> , 2010 , 23, 1191-200	9.8	265
76	Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. <i>Human Pathology</i> , 2010 , 41, 172-80	3.7	49
75	Genomic and biological characterization of exon 4 KRAS mutations in human cancer. <i>Cancer Research</i> , 2010 , 70, 5901-11	10.1	218
74	Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. <i>Thyroid</i> , 2010 , 20, 1085-93	6.2	71
73	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 9435-40	11.5	196
72	Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 2092-8	5.6	590
71	Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 7979-84	11.5	92
70	Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. <i>Cancer Research</i> , 2009 , 69, 4885-93	10.1	403
69	Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. <i>Current Opinion in Cell Biology</i> , 2009 , 21, 296-303	9	94
68	Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 4331-41	5.6	469
67	Molecular pathology of thyroid cancer: diagnostic and clinical implications. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 955-69	6.5	119
66	RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. <i>Cancer Research</i> , 2008 , 68, 4183-91	10.1	76

65	BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2194-201	5.6	107
64	Refractory thyroid cancer: a paradigm shift in treatment is not far off. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4701-4	2.2	47
63	Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. <i>Endocrine-Related Cancer</i> , 2008 , 15, 1069-74	5.7	266
62	The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. <i>Cancer Research</i> , 2007 , 67, 6956-64	10.1	91
61	The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations. <i>Transactions of the American Clinical and Climatological Association</i> , 2007 , 118, 253-61	0.9	4
60	Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006 , 2, 180-1		25
59	Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. <i>Cancer Research</i> , 2006 , 66, 6521-9	10.1	112
58	Welcome from the new Editor-in-Chief. <i>Endocrine-Related Cancer</i> , 2006 , 13, 1	5.7	3
57	Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. <i>Clinical Cancer Research</i> , 2006 , 12, 1785-93	12.9	122
56	Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. <i>Journal of Biological Chemistry</i> , 2006 , 281, 3800-9	5.4	74
55	BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. <i>Endocrinology</i> , 2006 , 147, 1014-9	4.8	99
54	BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer. <i>Cell Cycle</i> , 2005 , 4, 547-8	4.7	17
53	Why Thyroid Cancer?. <i>Thyroid</i> , 2005 , 15, 303-304	6.2	10
52	Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. <i>Cancer Research</i> , 2005 , 65, 2465-73	10.1	174
51	Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. <i>Cancer Research</i> , 2005 , 65, 4238-45	10.1	310
50	Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. <i>Journal of Clinical Investigation</i> , 2005 , 115, 94-101	15.9	307
49	Genetics of papillary thyroid cancer initiation: implications for therapy. <i>Transactions of the American Clinical and Climatological Association</i> , 2005 , 116, 259-69; discussion 269-71	0.9	35
48	Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5175-80	5.6	232

47	Challenging dogma in thyroid cancer molecular genetics--role of RET/PTC and BRAF in tumor initiation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4264-6	5.6	69
46	Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. <i>Cancer Letters</i> , 2004 , 209, 1-6	9.9	131
45	Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. <i>Oncogene</i> , 2003 , 22, 246-55	9.2	45
44	RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. <i>Oncogene</i> , 2003 , 22, 4406-12	9.2	134
43	Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells. <i>Oncogene</i> , 2003 , 22, 6830-8	9.2	19
42	BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5399-404	5.6	836
41	Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. <i>Molecular Endocrinology</i> , 2003 , 17, 1425-36		62
40	Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway. <i>Journal of Biological Chemistry</i> , 2003 , 278, 52131-8	5.4	18
39	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. <i>Cancer Research</i> , 2003 , 63, 1454-7	10.1	977
38	Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1. <i>Clinical Endocrinology</i> , 2002 , 56, 341-50	3.4	49
37	Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy. <i>Journal of Biological Chemistry</i> , 2002 , 277, 21285-90	5.4	39
36	Perspective: lessons learned from molecular genetic studies of thyroid cancer--insights into pathogenesis and tumor-specific therapeutic targets. <i>Endocrinology</i> , 2002 , 143, 2025-8	4.8	46
35	Minireview: branched from the start--distinct oncogenic initiating events may determine tumor fate in the thyroid. <i>Molecular Endocrinology</i> , 2002 , 16, 903-11		101
34	Isozyme-specific abnormalities of PKC in thyroid cancer: evidence for post-transcriptional changes in PKC epsilon. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 2150-9	5.6	28
33	Spontaneous occurrence of an inhibitor of protein kinase C localization in a thyroid cancer cell line: role in thyroid tumorigenesis. <i>Advances in Enzyme Regulation</i> , 2001 , 41, 87-97		3
32	Genetic markers in thyroid neoplasia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2001 , 30, 493-513, x	5.5	17
31	The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. <i>Oncogene</i> , 2000 , 19, 3948-54	9.2	148
30	Conditional apoptosis induced by oncogenic ras in thyroid cells. <i>Molecular Endocrinology</i> , 2000 , 14, 1725-38		48

29	Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. <i>Science</i> , 2000 , 290, 138-41	33.3	397
28	Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. <i>Journal of Biological Chemistry</i> , 1999 , 274, 23414-25	5.4	57
27	Frequent loss of heterozygosity at chromosome 3p14.2-3p21 in human pancreatic islet cell tumours. <i>Clinical Endocrinology</i> , 1999 , 51, 27-33	3.4	29
26	Prevalence of minisatellite and microsatellite instability in radiation-induced post-Chernobyl pediatric thyroid carcinomas. <i>Oncogene</i> , 1998 , 17, 1983-8	9.2	25
25	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. <i>Cancer</i> , 1998 , 83, 2185-2193	6.4	59
24	ret rearrangements in Japanese pediatric and adult papillary thyroid cancers. <i>Thyroid</i> , 1998 , 8, 485-9	6.2	63
23	Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas 1998 , 83, 2185		3
22	Aortic smooth muscle cells interact with tenascin-C through its fibrinogen-like domain. <i>Journal of Biological Chemistry</i> , 1997 , 272, 32798-803	5.4	32
21	Risk factors for thyroid cancer. <i>Trends in Endocrinology and Metabolism</i> , 1997 , 8, 20-5	8.8	14
20	Prevalence, Significance, and Biological Behavior of ret/PTC Associated Papillary Thyroid Carcinoma. Author's Response 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2016-2017	5.6	3
19	Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro. <i>Circulation Research</i> , 1996 , 78, 589-95	15.7	66
18	Tumor suppressor genes in human thyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers. <i>Journal of Endocrinological Investigation</i> , 1995 , 18, 140-2	5.2	30
17	Molecular pathogenesis of pituitary tumours. <i>Baillieres Clinical Endocrinology and Metabolism</i> , 1995 , 9, 203-23		16
16	Characteristics of follicular tumors and nonneoplastic thyroid lesions in children and adolescents exposed to radiation as a result of the Chernobyl disaster. <i>Cancer</i> , 1995 , 76, 900-9	6.4	40
15	Molecular genetics of human thyroid neoplasms. <i>Annual Review of Medicine</i> , 1994 , 45, 45-52	17.4	49
14	Stimulation of rat vascular smooth muscle cell glycosaminoglycan production by angiotensin II. <i>Atherosclerosis</i> , 1994 , 111, 55-64	3.1	18
13	Effects of hypophysectomy on vascular insulin-like growth factor-I gene expression after balloon denudation in rats. <i>Atherosclerosis</i> , 1992 , 93, 115-22	3.1	31
12	Growth factors, cytokines, and vascular injury. <i>Trends in Cardiovascular Medicine</i> , 1992 , 2, 90-4	6.9	16

11	Allelotype of human thyroid tumors: loss of chromosome 11q13 sequences in follicular neoplasms. <i>Molecular Endocrinology</i> , 1991 , 5, 1873-9		86
10	Solitary polyclonal autonomous thyroid nodule: a rare cause of childhood hyperthyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 72, 1108-12	5.6	20
9	Transforming DNA sequences present in human prolactin-secreting pituitary tumors. <i>Molecular Endocrinology</i> , 1991 , 5, 1687-95		63
8	A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. <i>Journal of the American College of Cardiology</i> , 1991 , 17, 758-69	15.1	484
7	Clonal origin of pituitary adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 71, 1427-33	5.6	458
6	Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. <i>Molecular Endocrinology</i> , 1990 , 4, 1474-9		292
5	H-ras protooncogene mutations in human thyroid neoplasms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 71, 223-9	5.6	92
4	Expression of the myc cellular proto-oncogene in human thyroid tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986 , 63, 1170-3	5.6	39
3	Isolation and characterization of rat-mouse somatic cell hybrids secreting growth hormone and prolactin. <i>Experimental Cell Research</i> , 1986 , 162, 475-85	4.2	0
2	Bromocriptine inhibits incorporation of [3H]thymidine into rat pituitary tumor cells. <i>Brain Research</i> , 1986 , 369, 83-90	3.7	6
1	Oncogenic events and therapeutic targets in thyroid cancer704-711		